Breaking News, Financial News

Emergent BioSolutions 3Q Results

Completes acquisition of worldwide rights to TEMBEXA; Anthrax vaccines revenue increases $8.6 million in the quarter.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Emergent BioSolutions 3Q Revenue: $240 million (-27%) 3Q Loss: $75.7 million (loss of $32.7 million 3Q21) YTD Revenue: $790 million (-26%) YTD Loss: $135.8 (earnings were $41.6 million YTD21) Comments: Revenues from CDMO services decreased $76.4 million in the quarter largely due to lower combined revenues of $59.1 million from AstraZeneca and Janssen reflecting the impact of reduced production activities at the Bayview facility as a result of a cessation of manufacturing activities under t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters